Figure 5: (A) Complement-dependent cytotoxicity (CDC) assay to demonstrate the effect of mRP215 Mab and its humanized form, hRP215 Mab, on the complementdependent cell lysis of OC-3-VGH ovarian cancer cells (2 hour incubation). Lane 1: no treatment (control); Lane 2: 3 μL freshly prepared rabbit baby complement/mL (C); Lane 3: normal human IgG (10 µg/ml plus complement) (NhIgG+C); Lane 4: normal mouse IgG (10 µg/ml plus complement)(NmIgG+C); Lane 5: hRP215 (10 µg/ml plus complement) (hRP215+C); Lane 6: mRP215 (10 µg/ml plus complement) (mRP215+C). Statistical significance at * P<0.01and ** P<0.001 with error bar indicated for duplicated experiments. (B) Similar experiments of mGHR106 Mab and its humanized form, hRP215 Mab on the complement-dependent cell lysis of OC-3-VGH ovarian cancer cell. See Reference [23,27].